Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00498602

Enrollment

160

Registered

2007-07-10

Start date

2007-11-30

Completion date

2013-02-28

Last updated

2016-01-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Brief summary

To access the safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization, in subjects with mild to moderate Alzheimer's disease.

Interventions

BIOLOGICALACC-001 + QS-21

IM injection, ACC-001 (3ug, or 10ug, or 30ug) + QS-21 50ug at Day 1 and weeks 4, 12, 26, and 52

BIOLOGICALQS-21

IM injection, QS-21 (50 ug) at Day 1 and weeks 4, 12, 26, and 52

OTHERDiluent: Phosphate Buffered Saline

IM injection, PBS Diluent at Day 1 and weeks 4, 12, 26, and 52

BIOLOGICALACC-001

IM injection, ACC 001 (10 ug, 30ug) at Day 1 and weeks 4, 12, 26, and 52

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

50 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of mild to moderate Alzheimer's disease * Age 50-85 * Mini Mental State Examination (MMSE) 16-26 Other criteria apply

Exclusion criteria

* Significant Neurological Disease * Major psychiatric disorder * Clinically significant systemic illness Other

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)	approximately 110 weeks, including a 6-week screening period, 52 weeks of dosing and 54 weeks for follow-up after the last dose	An AE was any untoward, undesired, or unplanned clinical event in the form of signs, symptoms, disease, or laboratory or physiologic observations occurring in a person given study drug or in a sponsor's clinical study. The event did not need to be causally related to the study drug or the clinical studies. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Secondary

Measure	Time frame	Description
Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Baseline, Week 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	The lower limit of quantification (LLOQ) was 100 U/mL and when the assay result was below LLOQ (100 U/mL), 50 U/mL was imputed for IgG.
GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Baseline, Week 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	The LLOQ was 50 U/mL and when the assay result was below LLOQ (50 U/mL), 25 U/mL was imputed for IgM.
Change From Baseline GMTs of Anti-A-beta IgG Subtypes Using ELISA at Visits Where an IgG Total Response is Measurable (at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104 if Applicable)	Baseline, Week 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	IgG subtypes were not assessed

Countries

United States

Participant flow

Recruitment details

Planned duration was approximately 110 weeks (including 6 week screening period, 52 weeks of dosing, and 52 weeks of follow-up). Participants who completed the NCT00498602 study through Week 78 had the option to exit after this time point, for continued treatment and follow-up under extension protocol extension protocol NCT00960531.

Pre-assignment details

The Basic Results disclose pooled data from studies NCT00479557 and NCT00498602.

Participants by arm

Arm	Count
ACC 3 μg+QS-21 Participants received 3 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.	36
ACC 10 μg+QS-21 Participants received 10 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.	61
ACC 30 μg+QS-21 Participants received 30 μg of ACC-001 and 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.	40
ACC 10 μg Participants received 10 μg of ACC-001. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.	35
ACC 30 μg Participants received 30 μg of ACC-001. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.	12
QS-21 Alone Participants received 50 μg of QS-21. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.	44
Phosphate Buffered Saline Participants received PBS. Test article was given by intramuscular injection into the deltoid muscle at 0, 1, 3, 6, and 12 months.	17
Total	245

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004	FG005	FG006
Overall Study	Adverse Event (AE) related to Study Drug	1	0	3	2	0	1	0
Overall Study	AE not related to Study Drug	1	3	0	0	2	2	1
Overall Study	Caregiver Request	2	2	2	0	1	2	0
Overall Study	Death	0	0	0	0	0	1	0
Overall Study	Investigator Request	0	0	1	0	0	0	0
Overall Study	Lack of Efficacy	1	0	0	0	0	0	0
Overall Study	Lost to Follow-up	0	2	0	2	0	0	0
Overall Study	Other	2	3	1	0	0	3	0
Overall Study	Subject Request	3	0	1	1	1	4	1

Baseline characteristics

Characteristic	Total	Phosphate Buffered Saline	QS-21 Alone	ACC 30 μg	ACC 10 μg	ACC 30 μg+QS-21	ACC 10 μg+QS-21	ACC 3 μg+QS-21
Age, Continuous	69.1 Years STANDARD_DEVIATION 8.87	69.4 Years STANDARD_DEVIATION 7.82	68.8 Years STANDARD_DEVIATION 8.07	70.9 Years STANDARD_DEVIATION 9.59	71.9 Years STANDARD_DEVIATION 8.96	69.0 Years STANDARD_DEVIATION 9.27	69.3 Years STANDARD_DEVIATION 9.57	65.7 Years STANDARD_DEVIATION 7.75
Mini-Mental State Examination (MMSE) Score	21.4 score STANDARD_DEVIATION 3.13	21.2 score STANDARD_DEVIATION 3.17	21.7 score STANDARD_DEVIATION 3.11	21.8 score STANDARD_DEVIATION 3.6	21.6 score STANDARD_DEVIATION 3.16	21.0 score STANDARD_DEVIATION 2.92	21.4 score STANDARD_DEVIATION 3.38	21.4 score STANDARD_DEVIATION 2.96
MMSE Stratum High (21 - 26)	161 number of participants	11 number of participants	29 number of participants	8 number of participants	23 number of participants	24 number of participants	40 number of participants	26 number of participants
MMSE Stratum Low (16 - 20)	84 number of participants	6 number of participants	15 number of participants	4 number of participants	12 number of participants	16 number of participants	21 number of participants	10 number of participants
Race/Ethnicity, Customized Asian	1 number of participants	0 number of participants	0 number of participants	1 number of participants	0 number of participants	0 number of participants	0 number of participants	0 number of participants
Race/Ethnicity, Customized Black or African American	3 number of participants	0 number of participants	1 number of participants	0 number of participants	0 number of participants	1 number of participants	0 number of participants	1 number of participants
Race/Ethnicity, Customized Other	5 number of participants	0 number of participants	0 number of participants	0 number of participants	1 number of participants	1 number of participants	1 number of participants	2 number of participants
Race/Ethnicity, Customized White	236 number of participants	17 number of participants	43 number of participants	11 number of participants	34 number of participants	38 number of participants	60 number of participants	33 number of participants
Sex: Female, Male Female	139 Participants	14 Participants	31 Participants	8 Participants	19 Participants	22 Participants	29 Participants	16 Participants
Sex: Female, Male Male	106 Participants	3 Participants	13 Participants	4 Participants	16 Participants	18 Participants	32 Participants	20 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —	— / —	— / —	— / —
other Total, other adverse events	34 / 36	48 / 60	35 / 40	28 / 35	10 / 12	40 / 44	17 / 17
serious Total, serious adverse events	6 / 36	11 / 60	7 / 40	5 / 35	5 / 12	5 / 44	3 / 17

Outcome results

Primary

Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)

An AE was any untoward, undesired, or unplanned clinical event in the form of signs, symptoms, disease, or laboratory or physiologic observations occurring in a person given study drug or in a sponsor's clinical study. The event did not need to be causally related to the study drug or the clinical studies. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame: approximately 110 weeks, including a 6-week screening period, 52 weeks of dosing and 54 weeks for follow-up after the last dose

Population: The safety population included all randomized participants with documented use of at least one dose of study drug.

Arm	Measure	Group	Value (NUMBER)
ACC 3 μg+QS-21	Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)	Percentage of participants with SAEs	16.7 percentage of participants
ACC 3 μg+QS-21	Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)	Percentage of participants with AEs	97.2 percentage of participants
ACC 10 μg+QS-21	Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)	Percentage of participants with SAEs	18.3 percentage of participants
ACC 10 μg+QS-21	Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)	Percentage of participants with AEs	93.3 percentage of participants
ACC 30 μg+QS-21	Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)	Percentage of participants with SAEs	17.5 percentage of participants
ACC 30 μg+QS-21	Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)	Percentage of participants with AEs	90.0 percentage of participants
ACC 10 μg	Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)	Percentage of participants with SAEs	14.3 percentage of participants
ACC 10 μg	Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)	Percentage of participants with AEs	91.4 percentage of participants
ACC 30 μg	Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)	Percentage of participants with SAEs	41.7 percentage of participants
ACC 30 μg	Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)	Percentage of participants with AEs	83.3 percentage of participants
QS-21 Alone	Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)	Percentage of participants with SAEs	11.4 percentage of participants
QS-21 Alone	Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)	Percentage of participants with AEs	90.9 percentage of participants
Phosphate Buffered Saline	Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)	Percentage of participants with SAEs	17.6 percentage of participants
Phosphate Buffered Saline	Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)	Percentage of participants with AEs	100 percentage of participants

Secondary

Change From Baseline GMTs of Anti-A-beta IgG Subtypes Using ELISA at Visits Where an IgG Total Response is Measurable (at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104 if Applicable)

IgG subtypes were not assessed

Time frame: Baseline, Week 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104

Secondary

Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104

The lower limit of quantification (LLOQ) was 100 U/mL and when the assay result was below LLOQ (100 U/mL), 50 U/mL was imputed for IgG.

Time frame: Baseline, Week 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104

Population: The immunogenicity population included all randomized participants with documented injection of at least one dose of study drug and at least one immunogenicity data point collected.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
ACC 3 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 40 (N: 32, 54, 33, 33, 9, 37, 15)	1167.3 U/mL
ACC 3 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 6 (N: 36, 58, 37, 33, 12, 41, 16)	634.8 U/mL
ACC 3 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 4 (N: 35, 57, 38, 31, 12, 43, 16)	53.2 U/mL
ACC 3 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 56 (N: 31, 52, 34, 32, 9, 34, 15)	2635.7 U/mL
ACC 3 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 91 (N: 15, 9, 3, 8, 2, 6, 2)	1824.6 U/mL
ACC 3 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 16 (N: 33, 59, 38, 34, 12, 41, 16)	996.1 U/mL
ACC 3 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 2 (N: 35, 60, 39, 35, 12, 43, 16)	56.6 U/mL
ACC 3 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 54 (N: 27, 51, 30, 29, 9, 29, 14)	2031.6 U/mL
ACC 3 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 30 (N: 33, 56, 36, 32, 10, 38, 16)	2028.9 U/mL
ACC 3 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 50 (N: 29, 53, 33, 33, 9, 36, 16)	937.3 U/mL
ACC 3 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 24 (N: 34, 58, 37, 33, 10, 40, 16)	547.8 U/mL
ACC 3 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 14 (N: 33, 52, 39, 31, 11, 33, 14)	907.5 U/mL
ACC 3 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 66 (N: 31, 54, 34, 31, 9, 33, 15)	1372.0 U/mL
ACC 3 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 104 (N: 15, 9, 4, 7, 1, 6, 2)	1326.1 U/mL
ACC 3 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 10 (N: 34, 59, 40, 33, 12, 43, 17)	292.3 U/mL
ACC 3 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 8 (N: 33, 57, 39, 33, 12, 41, 17)	497.4 U/mL
ACC 3 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 28 (N: 31, 51, 33, 29, 8, 36, 16)	2011.2 U/mL
ACC 3 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 78 (N: 31, 52, 32, 32, 8, 32, 14)	1108.4 U/mL
ACC 3 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Baseline (N: 36, 59, 40, 35, 12, 44, 17)	50.0 U/mL
ACC 10 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 24 (N: 34, 58, 37, 33, 10, 40, 16)	1827.6 U/mL
ACC 10 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 54 (N: 27, 51, 30, 29, 9, 29, 14)	5744.6 U/mL
ACC 10 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 40 (N: 32, 54, 33, 33, 9, 37, 15)	2147.2 U/mL
ACC 10 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 50 (N: 29, 53, 33, 33, 9, 36, 16)	1364.4 U/mL
ACC 10 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Baseline (N: 36, 59, 40, 35, 12, 44, 17)	50.0 U/mL
ACC 10 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 28 (N: 31, 51, 33, 29, 8, 36, 16)	4299.6 U/mL
ACC 10 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 91 (N: 15, 9, 3, 8, 2, 6, 2)	2497.0 U/mL
ACC 10 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 2 (N: 35, 60, 39, 35, 12, 43, 16)	69.0 U/mL
ACC 10 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 4 (N: 35, 57, 38, 31, 12, 43, 16)	77.1 U/mL
ACC 10 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 78 (N: 31, 52, 32, 32, 8, 32, 14)	1867.5 U/mL
ACC 10 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 6 (N: 36, 58, 37, 33, 12, 41, 16)	1089.4 U/mL
ACC 10 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 8 (N: 33, 57, 39, 33, 12, 41, 17)	885.2 U/mL
ACC 10 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 104 (N: 15, 9, 4, 7, 1, 6, 2)	2212.7 U/mL
ACC 10 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 66 (N: 31, 54, 34, 31, 9, 33, 15)	2867.4 U/mL
ACC 10 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 10 (N: 34, 59, 40, 33, 12, 43, 17)	762.8 U/mL
ACC 10 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 14 (N: 33, 52, 39, 31, 11, 33, 14)	2892.3 U/mL
ACC 10 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 56 (N: 31, 52, 34, 32, 9, 34, 15)	5906.1 U/mL
ACC 10 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 16 (N: 33, 59, 38, 34, 12, 41, 16)	3273.2 U/mL
ACC 10 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 30 (N: 33, 56, 36, 32, 10, 38, 16)	4316.8 U/mL
ACC 30 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 8 (N: 33, 57, 39, 33, 12, 41, 17)	1098.2 U/mL
ACC 30 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 30 (N: 33, 56, 36, 32, 10, 38, 16)	4713.0 U/mL
ACC 30 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Baseline (N: 36, 59, 40, 35, 12, 44, 17)	50.0 U/mL
ACC 30 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 50 (N: 29, 53, 33, 33, 9, 36, 16)	1262.3 U/mL
ACC 30 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 54 (N: 27, 51, 30, 29, 9, 29, 14)	6677.3 U/mL
ACC 30 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 14 (N: 33, 52, 39, 31, 11, 33, 14)	3136.8 U/mL
ACC 30 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 16 (N: 33, 59, 38, 34, 12, 41, 16)	3324.7 U/mL
ACC 30 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 66 (N: 31, 54, 34, 31, 9, 33, 15)	2882.2 U/mL
ACC 30 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 2 (N: 35, 60, 39, 35, 12, 43, 16)	86.5 U/mL
ACC 30 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 40 (N: 32, 54, 33, 33, 9, 37, 15)	2292.9 U/mL
ACC 30 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 28 (N: 31, 51, 33, 29, 8, 36, 16)	5407.7 U/mL
ACC 30 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 91 (N: 15, 9, 3, 8, 2, 6, 2)	543.0 U/mL
ACC 30 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 104 (N: 15, 9, 4, 7, 1, 6, 2)	243.3 U/mL
ACC 30 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 24 (N: 34, 58, 37, 33, 10, 40, 16)	1231.3 U/mL
ACC 30 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 56 (N: 31, 52, 34, 32, 9, 34, 15)	7642.5 U/mL
ACC 30 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 4 (N: 35, 57, 38, 31, 12, 43, 16)	82.8 U/mL
ACC 30 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 10 (N: 34, 59, 40, 33, 12, 43, 17)	878.5 U/mL
ACC 30 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 6 (N: 36, 58, 37, 33, 12, 41, 16)	1343.5 U/mL
ACC 30 μg+QS-21	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 78 (N: 31, 52, 32, 32, 8, 32, 14)	1338.1 U/mL
ACC 10 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 30 (N: 33, 56, 36, 32, 10, 38, 16)	110.4 U/mL
ACC 10 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 6 (N: 36, 58, 37, 33, 12, 41, 16)	73.4 U/mL
ACC 10 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 104 (N: 15, 9, 4, 7, 1, 6, 2)	98.9 U/mL
ACC 10 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 91 (N: 15, 9, 3, 8, 2, 6, 2)	76.8 U/mL
ACC 10 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 66 (N: 31, 54, 34, 31, 9, 33, 15)	166.3 U/mL
ACC 10 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 40 (N: 32, 54, 33, 33, 9, 37, 15)	97.2 U/mL
ACC 10 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 24 (N: 34, 58, 37, 33, 10, 40, 16)	76.1 U/mL
ACC 10 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 8 (N: 33, 57, 39, 33, 12, 41, 17)	66.3 U/mL
ACC 10 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 16 (N: 33, 59, 38, 34, 12, 41, 16)	91.7 U/mL
ACC 10 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 10 (N: 34, 59, 40, 33, 12, 43, 17)	77.0 U/mL
ACC 10 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 54 (N: 27, 51, 30, 29, 9, 29, 14)	160.6 U/mL
ACC 10 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 56 (N: 31, 52, 34, 32, 9, 34, 15)	159.2 U/mL
ACC 10 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 14 (N: 33, 52, 39, 31, 11, 33, 14)	89.6 U/mL
ACC 10 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 50 (N: 29, 53, 33, 33, 9, 36, 16)	80.7 U/mL
ACC 10 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 2 (N: 35, 60, 39, 35, 12, 43, 16)	51.7 U/mL
ACC 10 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 78 (N: 31, 52, 32, 32, 8, 32, 14)	142.7 U/mL
ACC 10 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Baseline (N: 36, 59, 40, 35, 12, 44, 17)	50.0 U/mL
ACC 10 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 4 (N: 35, 57, 38, 31, 12, 43, 16)	50.0 U/mL
ACC 10 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 28 (N: 31, 51, 33, 29, 8, 36, 16)	108.9 U/mL
ACC 30 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 8 (N: 33, 57, 39, 33, 12, 41, 17)	99.8 U/mL
ACC 30 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 28 (N: 31, 51, 33, 29, 8, 36, 16)	334.1 U/mL
ACC 30 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 30 (N: 33, 56, 36, 32, 10, 38, 16)	234.5 U/mL
ACC 30 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 40 (N: 32, 54, 33, 33, 9, 37, 15)	211.0 U/mL
ACC 30 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Baseline (N: 36, 59, 40, 35, 12, 44, 17)	50.0 U/mL
ACC 30 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 2 (N: 35, 60, 39, 35, 12, 43, 16)	50.0 U/mL
ACC 30 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 4 (N: 35, 57, 38, 31, 12, 43, 16)	50.0 U/mL
ACC 30 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 6 (N: 36, 58, 37, 33, 12, 41, 16)	103.7 U/mL
ACC 30 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 24 (N: 34, 58, 37, 33, 10, 40, 16)	139.1 U/mL
ACC 30 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 10 (N: 34, 59, 40, 33, 12, 43, 17)	94.9 U/mL
ACC 30 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 14 (N: 33, 52, 39, 31, 11, 33, 14)	199.4 U/mL
ACC 30 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 16 (N: 33, 59, 38, 34, 12, 41, 16)	133.9 U/mL
ACC 30 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 50 (N: 29, 53, 33, 33, 9, 36, 16)	168.4 U/mL
ACC 30 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 54 (N: 27, 51, 30, 29, 9, 29, 14)	491.6 U/mL
ACC 30 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 56 (N: 31, 52, 34, 32, 9, 34, 15)	463.7 U/mL
ACC 30 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 66 (N: 31, 54, 34, 31, 9, 33, 15)	280.0 U/mL
ACC 30 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 78 (N: 31, 52, 32, 32, 8, 32, 14)	256.1 U/mL
ACC 30 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 91 (N: 15, 9, 3, 8, 2, 6, 2)	50.0 U/mL
ACC 30 μg	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 104 (N: 15, 9, 4, 7, 1, 6, 2)	50.0 U/mL
QS-21 Alone	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 54 (N: 27, 51, 30, 29, 9, 29, 14)	55.0 U/mL
QS-21 Alone	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 4 (N: 35, 57, 38, 31, 12, 43, 16)	51.3 U/mL
QS-21 Alone	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 10 (N: 34, 59, 40, 33, 12, 43, 17)	53.0 U/mL
QS-21 Alone	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 24 (N: 34, 58, 37, 33, 10, 40, 16)	52.3 U/mL
QS-21 Alone	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 78 (N: 31, 52, 32, 32, 8, 32, 14)	53.6 U/mL
QS-21 Alone	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 14 (N: 33, 52, 39, 31, 11, 33, 14)	50.0 U/mL
QS-21 Alone	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 2 (N: 35, 60, 39, 35, 12, 43, 16)	52.5 U/mL
QS-21 Alone	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 8 (N: 33, 57, 39, 33, 12, 41, 17)	52.4 U/mL
QS-21 Alone	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Baseline (N: 36, 59, 40, 35, 12, 44, 17)	53.1 U/mL
QS-21 Alone	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 16 (N: 33, 59, 38, 34, 12, 41, 16)	52.6 U/mL
QS-21 Alone	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 104 (N: 15, 9, 4, 7, 1, 6, 2)	50.0 U/mL
QS-21 Alone	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 91 (N: 15, 9, 3, 8, 2, 6, 2)	50.0 U/mL
QS-21 Alone	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 28 (N: 31, 51, 33, 29, 8, 36, 16)	52.4 U/mL
QS-21 Alone	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 66 (N: 31, 54, 34, 31, 9, 33, 15)	63.5 U/mL
QS-21 Alone	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 50 (N: 29, 53, 33, 33, 9, 36, 16)	52.8 U/mL
QS-21 Alone	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 56 (N: 31, 52, 34, 32, 9, 34, 15)	53.4 U/mL
QS-21 Alone	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 40 (N: 32, 54, 33, 33, 9, 37, 15)	52.1 U/mL
QS-21 Alone	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 6 (N: 36, 58, 37, 33, 12, 41, 16)	50.0 U/mL
QS-21 Alone	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 30 (N: 33, 56, 36, 32, 10, 38, 16)	51.8 U/mL
Phosphate Buffered Saline	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 4 (N: 35, 57, 38, 31, 12, 43, 16)	50.0 U/mL
Phosphate Buffered Saline	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 28 (N: 31, 51, 33, 29, 8, 36, 16)	50.0 U/mL
Phosphate Buffered Saline	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 54 (N: 27, 51, 30, 29, 9, 29, 14)	50.0 U/mL
Phosphate Buffered Saline	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 14 (N: 33, 52, 39, 31, 11, 33, 14)	50.0 U/mL
Phosphate Buffered Saline	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 10 (N: 34, 59, 40, 33, 12, 43, 17)	50.0 U/mL
Phosphate Buffered Saline	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 56 (N: 31, 52, 34, 32, 9, 34, 15)	50.0 U/mL
Phosphate Buffered Saline	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 8 (N: 33, 57, 39, 33, 12, 41, 17)	50.0 U/mL
Phosphate Buffered Saline	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 6 (N: 36, 58, 37, 33, 12, 41, 16)	50.0 U/mL
Phosphate Buffered Saline	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 24 (N: 34, 58, 37, 33, 10, 40, 16)	50.0 U/mL
Phosphate Buffered Saline	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 66 (N: 31, 54, 34, 31, 9, 33, 15)	50.0 U/mL
Phosphate Buffered Saline	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 16 (N: 33, 59, 38, 34, 12, 41, 16)	50.0 U/mL
Phosphate Buffered Saline	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 2 (N: 35, 60, 39, 35, 12, 43, 16)	50.0 U/mL
Phosphate Buffered Saline	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 78 (N: 31, 52, 32, 32, 8, 32, 14)	50.0 U/mL
Phosphate Buffered Saline	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Baseline (N: 36, 59, 40, 35, 12, 44, 17)	50.0 U/mL
Phosphate Buffered Saline	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 104 (N: 15, 9, 4, 7, 1, 6, 2)	50.0 U/mL
Phosphate Buffered Saline	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 40 (N: 32, 54, 33, 33, 9, 37, 15)	50.0 U/mL
Phosphate Buffered Saline	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 91 (N: 15, 9, 3, 8, 2, 6, 2)	50.0 U/mL
Phosphate Buffered Saline	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 50 (N: 29, 53, 33, 33, 9, 36, 16)	50.0 U/mL
Phosphate Buffered Saline	Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 30 (N: 33, 56, 36, 32, 10, 38, 16)	50.0 U/mL

Secondary

GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104

The LLOQ was 50 U/mL and when the assay result was below LLOQ (50 U/mL), 25 U/mL was imputed for IgM.

Time frame: Baseline, Week 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104

Population: The immunogenicity population included all randomized participants with documented injection of at least one dose of study drug and at least one immunogenicity data point collected.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
ACC 3 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 10 (N: 34, 59, 40, 33, 12, 43, 17)	595.2 U/mL
ACC 3 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 91 (N: 15, 9, 3, 8, 2, 6, 2)	391.2 U/mL
ACC 3 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 16 (N: 33, 59, 38, 34, 12, 41, 16)	727.3 U/mL
ACC 3 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 14 (N: 33, 52, 39, 31, 11, 33, 14)	770.2 U/mL
ACC 3 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 2 (N: 35, 60, 39, 35, 12, 43, 16)	85.1 U/mL
ACC 3 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 78 (N: 31, 52, 32, 32, 8, 32, 14)	368.2 U/mL
ACC 3 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 66 (N: 31, 54, 34, 31, 9, 33, 15)	457.6 U/mL
ACC 3 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 56 (N: 31, 52, 34, 32, 9, 34, 15)	598.7 U/mL
ACC 3 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 54 (N: 27, 51, 30, 29, 9, 29, 14)	477.7 U/mL
ACC 3 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 4 (N: 35, 57, 38, 31, 12, 43, 16)	82.3 U/mL
ACC 3 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 50 (N: 29, 53, 33, 33, 9, 36, 16)	351.3 U/mL
ACC 3 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Baseline (N: 36, 59, 40, 35, 12, 44, 17)	32.3 U/mL
ACC 3 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 6 (N: 36, 58, 37, 33, 12, 41, 16)	626.5 U/mL
ACC 3 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 104 (N: 15, 9, 4, 7, 1, 6, 2)	299.1 U/mL
ACC 3 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 40 (N: 32, 54, 33, 33, 9, 37, 15)	559.0 U/mL
ACC 3 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 30 (N: 33, 56, 36, 32, 10, 38, 16)	717.3 U/mL
ACC 3 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 8 (N: 33, 57, 39, 33, 12, 41, 17)	758.9 U/mL
ACC 3 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 28 (N: 31, 51, 33, 29, 8, 36, 16)	669.0 U/mL
ACC 3 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 24 (N: 34, 58, 37, 33, 10, 40, 16)	461.3 U/mL
ACC 10 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 4 (N: 35, 57, 38, 31, 12, 43, 16)	123.4 U/mL
ACC 10 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 10 (N: 34, 59, 40, 33, 12, 43, 17)	1697.7 U/mL
ACC 10 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 104 (N: 15, 9, 4, 7, 1, 6, 2)	1561.8 U/mL
ACC 10 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 16 (N: 33, 59, 38, 34, 12, 41, 16)	3098.3 U/mL
ACC 10 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 50 (N: 29, 53, 33, 33, 9, 36, 16)	1049.6 U/mL
ACC 10 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 14 (N: 33, 52, 39, 31, 11, 33, 14)	2721.0 U/mL
ACC 10 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 30 (N: 33, 56, 36, 32, 10, 38, 16)	2259.4 U/mL
ACC 10 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 28 (N: 31, 51, 33, 29, 8, 36, 16)	1915.3 U/mL
ACC 10 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 2 (N: 35, 60, 39, 35, 12, 43, 16)	127.7 U/mL
ACC 10 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Baseline (N: 36, 59, 40, 35, 12, 44, 17)	38.2 U/mL
ACC 10 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 78 (N: 31, 52, 32, 32, 8, 32, 14)	1204.4 U/mL
ACC 10 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 40 (N: 32, 54, 33, 33, 9, 37, 15)	1351.6 U/mL
ACC 10 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 66 (N: 31, 54, 34, 31, 9, 33, 15)	1422.0 U/mL
ACC 10 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 24 (N: 34, 58, 37, 33, 10, 40, 16)	1862.5 U/mL
ACC 10 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 56 (N: 31, 52, 34, 32, 9, 34, 15)	1696.1 U/mL
ACC 10 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 6 (N: 36, 58, 37, 33, 12, 41, 16)	1283.8 U/mL
ACC 10 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 54 (N: 27, 51, 30, 29, 9, 29, 14)	1529.1 U/mL
ACC 10 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 8 (N: 33, 57, 39, 33, 12, 41, 17)	1903.8 U/mL
ACC 10 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 91 (N: 15, 9, 3, 8, 2, 6, 2)	1203.4 U/mL
ACC 30 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 40 (N: 32, 54, 33, 33, 9, 37, 15)	1855.9 U/mL
ACC 30 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Baseline (N: 36, 59, 40, 35, 12, 44, 17)	34.2 U/mL
ACC 30 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 2 (N: 35, 60, 39, 35, 12, 43, 16)	254.5 U/mL
ACC 30 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 4 (N: 35, 57, 38, 31, 12, 43, 16)	276.6 U/mL
ACC 30 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 6 (N: 36, 58, 37, 33, 12, 41, 16)	1736.6 U/mL
ACC 30 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 8 (N: 33, 57, 39, 33, 12, 41, 17)	2769.5 U/mL
ACC 30 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 10 (N: 34, 59, 40, 33, 12, 43, 17)	2598.1 U/mL
ACC 30 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 14 (N: 33, 52, 39, 31, 11, 33, 14)	5271.3 U/mL
ACC 30 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 16 (N: 33, 59, 38, 34, 12, 41, 16)	5666.4 U/mL
ACC 30 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 24 (N: 34, 58, 37, 33, 10, 40, 16)	2672.4 U/mL
ACC 30 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 28 (N: 31, 51, 33, 29, 8, 36, 16)	3593.2 U/mL
ACC 30 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 30 (N: 33, 56, 36, 32, 10, 38, 16)	4147.2 U/mL
ACC 30 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 50 (N: 29, 53, 33, 33, 9, 36, 16)	1246.4 U/mL
ACC 30 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 54 (N: 27, 51, 30, 29, 9, 29, 14)	2479.5 U/mL
ACC 30 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 56 (N: 31, 52, 34, 32, 9, 34, 15)	2681.8 U/mL
ACC 30 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 66 (N: 31, 54, 34, 31, 9, 33, 15)	1637.2 U/mL
ACC 30 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 78 (N: 31, 52, 32, 32, 8, 32, 14)	1217.7 U/mL
ACC 30 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 91 (N: 15, 9, 3, 8, 2, 6, 2)	679.2 U/mL
ACC 30 μg+QS-21	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 104 (N: 15, 9, 4, 7, 1, 6, 2)	620.3 U/mL
ACC 10 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 30 (N: 33, 56, 36, 32, 10, 38, 16)	128.4 U/mL
ACC 10 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 91 (N: 15, 9, 3, 8, 2, 6, 2)	98.9 U/mL
ACC 10 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 54 (N: 27, 51, 30, 29, 9, 29, 14)	121.1 U/mL
ACC 10 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Baseline (N: 36, 59, 40, 35, 12, 44, 17)	32.9 U/mL
ACC 10 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 6 (N: 36, 58, 37, 33, 12, 41, 16)	72.3 U/mL
ACC 10 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 50 (N: 29, 53, 33, 33, 9, 36, 16)	84.7 U/mL
ACC 10 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 4 (N: 35, 57, 38, 31, 12, 43, 16)	48.2 U/mL
ACC 10 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 14 (N: 33, 52, 39, 31, 11, 33, 14)	80.8 U/mL
ACC 10 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 78 (N: 31, 52, 32, 32, 8, 32, 14)	107.5 U/mL
ACC 10 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 10 (N: 34, 59, 40, 33, 12, 43, 17)	69.9 U/mL
ACC 10 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 8 (N: 33, 57, 39, 33, 12, 41, 17)	70.8 U/mL
ACC 10 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 40 (N: 32, 54, 33, 33, 9, 37, 15)	103.9 U/mL
ACC 10 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 28 (N: 31, 51, 33, 29, 8, 36, 16)	105.5 U/mL
ACC 10 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 16 (N: 33, 59, 38, 34, 12, 41, 16)	93.4 U/mL
ACC 10 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 66 (N: 31, 54, 34, 31, 9, 33, 15)	114.3 U/mL
ACC 10 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 104 (N: 15, 9, 4, 7, 1, 6, 2)	176.7 U/mL
ACC 10 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 56 (N: 31, 52, 34, 32, 9, 34, 15)	109.8 U/mL
ACC 10 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 24 (N: 34, 58, 37, 33, 10, 40, 16)	90.8 U/mL
ACC 10 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 2 (N: 35, 60, 39, 35, 12, 43, 16)	46.5 U/mL
ACC 30 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 104 (N: 15, 9, 4, 7, 1, 6, 2)	25.0 U/mL
ACC 30 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 91 (N: 15, 9, 3, 8, 2, 6, 2)	25.0 U/mL
ACC 30 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 24 (N: 34, 58, 37, 33, 10, 40, 16)	296.2 U/mL
ACC 30 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 8 (N: 33, 57, 39, 33, 12, 41, 17)	166.4 U/mL
ACC 30 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 28 (N: 31, 51, 33, 29, 8, 36, 16)	590.9 U/mL
ACC 30 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 6 (N: 36, 58, 37, 33, 12, 41, 16)	144.1 U/mL
ACC 30 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 30 (N: 33, 56, 36, 32, 10, 38, 16)	343.3 U/mL
ACC 30 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 4 (N: 35, 57, 38, 31, 12, 43, 16)	92.0 U/mL
ACC 30 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Baseline (N: 36, 59, 40, 35, 12, 44, 17)	40.3 U/mL
ACC 30 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 50 (N: 29, 53, 33, 33, 9, 36, 16)	294.6 U/mL
ACC 30 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 54 (N: 27, 51, 30, 29, 9, 29, 14)	436.9 U/mL
ACC 30 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 2 (N: 35, 60, 39, 35, 12, 43, 16)	76.9 U/mL
ACC 30 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 56 (N: 31, 52, 34, 32, 9, 34, 15)	438.5 U/mL
ACC 30 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 40 (N: 32, 54, 33, 33, 9, 37, 15)	311.9 U/mL
ACC 30 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 66 (N: 31, 54, 34, 31, 9, 33, 15)	342.1 U/mL
ACC 30 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 78 (N: 31, 52, 32, 32, 8, 32, 14)	346.0 U/mL
ACC 30 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 14 (N: 33, 52, 39, 31, 11, 33, 14)	290.7 U/mL
ACC 30 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 10 (N: 34, 59, 40, 33, 12, 43, 17)	157.1 U/mL
ACC 30 μg	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 16 (N: 33, 59, 38, 34, 12, 41, 16)	271.8 U/mL
QS-21 Alone	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 30 (N: 33, 56, 36, 32, 10, 38, 16)	37.8 U/mL
QS-21 Alone	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 54 (N: 27, 51, 30, 29, 9, 29, 14)	36.2 U/mL
QS-21 Alone	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 6 (N: 36, 58, 37, 33, 12, 41, 16)	31.1 U/mL
QS-21 Alone	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 14 (N: 33, 52, 39, 31, 11, 33, 14)	31.0 U/mL
QS-21 Alone	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 56 (N: 31, 52, 34, 32, 9, 34, 15)	34.3 U/mL
QS-21 Alone	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 40 (N: 32, 54, 33, 33, 9, 37, 15)	34.2 U/mL
QS-21 Alone	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 28 (N: 31, 51, 33, 29, 8, 36, 16)	31.3 U/mL
QS-21 Alone	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 66 (N: 31, 54, 34, 31, 9, 33, 15)	36.1 U/mL
QS-21 Alone	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 91 (N: 15, 9, 3, 8, 2, 6, 2)	28.3 U/mL
QS-21 Alone	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 16 (N: 33, 59, 38, 34, 12, 41, 16)	34.5 U/mL
QS-21 Alone	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 8 (N: 33, 57, 39, 33, 12, 41, 17)	31.0 U/mL
QS-21 Alone	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 78 (N: 31, 52, 32, 32, 8, 32, 14)	34.6 U/mL
QS-21 Alone	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Baseline (N: 36, 59, 40, 35, 12, 44, 17)	30.8 U/mL
QS-21 Alone	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 4 (N: 35, 57, 38, 31, 12, 43, 16)	33.2 U/mL
QS-21 Alone	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 10 (N: 34, 59, 40, 33, 12, 43, 17)	36.3 U/mL
QS-21 Alone	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 104 (N: 15, 9, 4, 7, 1, 6, 2)	25.0 U/mL
QS-21 Alone	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 50 (N: 29, 53, 33, 33, 9, 36, 16)	32.2 U/mL
QS-21 Alone	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 2 (N: 35, 60, 39, 35, 12, 43, 16)	31.5 U/mL
QS-21 Alone	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 24 (N: 34, 58, 37, 33, 10, 40, 16)	30.9 U/mL
Phosphate Buffered Saline	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 30 (N: 33, 56, 36, 32, 10, 38, 16)	25.0 U/mL
Phosphate Buffered Saline	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 24 (N: 34, 58, 37, 33, 10, 40, 16)	26.6 U/mL
Phosphate Buffered Saline	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 54 (N: 27, 51, 30, 29, 9, 29, 14)	27.2 U/mL
Phosphate Buffered Saline	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 8 (N: 33, 57, 39, 33, 12, 41, 17)	26.3 U/mL
Phosphate Buffered Saline	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 91 (N: 15, 9, 3, 8, 2, 6, 2)	25.0 U/mL
Phosphate Buffered Saline	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 104 (N: 15, 9, 4, 7, 1, 6, 2)	25.0 U/mL
Phosphate Buffered Saline	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 50 (N: 29, 53, 33, 33, 9, 36, 16)	25.0 U/mL
Phosphate Buffered Saline	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 4 (N: 35, 57, 38, 31, 12, 43, 16)	27.3 U/mL
Phosphate Buffered Saline	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 78 (N: 31, 52, 32, 32, 8, 32, 14)	28.9 U/mL
Phosphate Buffered Saline	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 56 (N: 31, 52, 34, 32, 9, 34, 15)	29.5 U/mL
Phosphate Buffered Saline	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Baseline (N: 36, 59, 40, 35, 12, 44, 17)	25.0 U/mL
Phosphate Buffered Saline	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 14 (N: 33, 52, 39, 31, 11, 33, 14)	25.0 U/mL
Phosphate Buffered Saline	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 28 (N: 31, 51, 33, 29, 8, 36, 16)	25.0 U/mL
Phosphate Buffered Saline	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 2 (N: 35, 60, 39, 35, 12, 43, 16)	26.5 U/mL
Phosphate Buffered Saline	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 16 (N: 33, 59, 38, 34, 12, 41, 16)	25.0 U/mL
Phosphate Buffered Saline	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 40 (N: 32, 54, 33, 33, 9, 37, 15)	25.0 U/mL
Phosphate Buffered Saline	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 66 (N: 31, 54, 34, 31, 9, 33, 15)	27.8 U/mL
Phosphate Buffered Saline	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 10 (N: 34, 59, 40, 33, 12, 43, 17)	27.3 U/mL
Phosphate Buffered Saline	GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104	Week 6 (N: 36, 58, 37, 33, 12, 41, 16)	25.0 U/mL

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Conditions

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)

Change From Baseline GMTs of Anti-A-beta IgG Subtypes Using ELISA at Visits Where an IgG Total Response is Measurable (at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104 if Applicable)

Geometric Mean Titers (GMTs) of Anti-A-beta Immunoglobulin G (IgG) Total Using an Enzyme-linked Immunosorbent Assay (ELISA) at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104

GMTs of Anti-A-beta Immunoglobulin M (IgM) Using ELISA at Weeks 2, 4, 6, 8, 10, 14, 16, 24, 28, 30, 40, 50, 54, 56, 66, 78, 91, and 104